INDRAYANI BIOTECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/11/2020 ,inter alia, to consider and approve 1. To consider, approve, adopt the merged financials of the Company for the year 2019-2020 in furtherance to the order of the National Company Law Tribunal, Chennai dated 05.08.2020. 2. Any other business with the permission of the chair.

1. To consider and approve unaudited financial results for the quarter/half year ended 30th September 2020 2. To take on record the limited review report of the Auditor for the half year ended September 2020.

INDRAYANI BIOTECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2020 ,inter alia, to consider and approve Pursuant to provisions of Regulation 29 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on FRIDAY, the 13th day of November, 2020, inter-alia for the following purpose: 1. To consider and adopt standalone and Consolidated Balance sheet of Indrayani Biotech Limited for the year 2019-2020 pursuant to merger Order dated 05-08-2020 2. To consider and approve unaudited financial results for the quarter/half year ended 30th September 2020

With reference to captioned subject, we would like to inform you that the Company has Incorporated a wholly owned subsidiary company'IBL Healthcare Private Limited' on 30.10.2020

Please find enclosed herewith the Compliance Certificate issued by a Practicing Company Secretary pursuant to Regulation 40(9) & 40 (10) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year period ended 30TH September 2020 in the prescribed format.

Indrayani Biotech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here

Certificate under regulation 74(5) of the SEBI (Depositories and Participants ) Regulations 2018

Pursuant to Regulation 7 (3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which 1s a SEBI approved category-I, Registrar & Transfer Agent, registered with Securities and Exchange Board of India (SEBI Registration Number ; INRO00004058).

. Adoption of Consolidated Balance sheet for the year 2018-2019 of Indrayani Biotech Limited along with two transferor Companies i. e Helios Solutions Limited and A diet Express Hospitality services Limited pursuant to the order of merger dated 05.08.2020 b. The Company has initiated the process to incorporate a wholly owned subsidiary for its health care segment. The Main object of the subsidiary would be to establish, maintain and run eye care hospitals. The Subsidiary will also invest and partner in Limited Liability Partnerships to be incorporated for the purpose of establishing, maintaining and operating eye care centres with the name of 'DEEPAM EYE HOSPITAL' and five such centres are to be opened around Chennai and Tamilnadu before the end of 2021. The Board authorises Mr. Kasi Raman Sayee Sundar, Managing Director of the Company to do all further acts and execute necessary documents for giving effect to the aforesaid item.

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Roopa RavikumarDesignation :- Company Secretary and Compliance Officer